Correction To: Unexpected Benefit From Alpelisib and Fulvestrant in a Woman With Highly Pre-Treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
Clinical Drug Investigation - United Kingdom
doi 10.1007/s40261-019-00748-x
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2019
Authors
Publisher
Springer Science and Business Media LLC